Management of pulmonary neuroendocrine tumors
- 557 Downloads
Neuroendocrine tumors (NETs) of the lung are divided into 4 major types: small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), atypical carcinoid (AC) or typical carcinoid (TC). Each classification has distinctly different treatment paradigms, making an accurate initial diagnosis essential. The inconsistent clinical presentation of this disease, however, makes this difficult. The objective of this manuscript is to detail the diagnosis and management of the well differentiated pulmonary carcinoid (PC) tumors. A multidisciplinary approach to work up and treatment should be utilized for each patient. A multimodal radiological work-up is used for diagnosis, with contrast enhanced CT predominantly utilized and functional imaging techniques. A definitive diagnosis is based on tissue findings. Surgical management remains the mainstay of therapy and can be curative. In those with advanced disease, medical treatments consist of somatostatin analog (SSA) therapy, targeted therapy, chemotherapy or peptide receptor radionuclide therapy. SSAs are the standard of care in those with metastatic NETs, using either Octreotide long acting repeatable (LAR) or lanreotide as reasonable options, despite a scarcity of prospective data in PCs. Targeted therapies consist of everolimus which is approved for use in PCs, with various studies showing mixed results with other targeted agents. Additionally, radionuclide therapy may be used and has been shown to increase survival and to reduce symptoms in some studies. Prospective trials are needed to determine other strategies that may be beneficial in PCs as well as sequencing of therapy. Successful diagnosis and optimal treatment relies on a multidisciplinary approach in patients with lung NETs. Clinical trials should be used in appropriate patients.
KeywordsBronchial carcinoid Neuroendocrine tumor Lung carcinoid
Compliance with ethical standards
Conflict of interest
Robert A. Ramirez, DO serves as a consultant for Ipsen Biophamaceuticals Inc. and Bio Theranostics Inc. as well as a speaker for Merck & Co. Inc., Genetech, Astra Zeneca and Ipsen Biopharmaceuticals. No other authors have conflicts of interest to disclose.
Human and animal studies
No humans or animals were used in this study.
None to disclose.
- 29.Horsch D, Schmid KW, Anlauf M, et al. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany. Oncol Res Treat. 2014;37(5):266–76.CrossRefPubMedGoogle Scholar
- 31.Travis WD, Brambilla W, Muller-Hermelink HK, Harris CC. World health organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.Google Scholar
- 36.Ramirez RA, Beyer DT, Diebold AE, et al. Clinical and pathologic characteristics of bronchial carcinoid tumors: a single institution review. J Thorac Oncol. 2015;10(9):S749–50.Google Scholar
- 45.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology neuroendocrine tumors. National Comprehensive Cancer Network Web site. https://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf. Updated Version 2.2017. Accessed 11 May 2017.
- 51.Davini F, Gonfiotti A, Comin C, Caldarella A, Mannini F, Janni A. Typical and atypical carcinoid tumours: 20-year experience with 89 patients. J Cardiovasc Surg. 2009;50(6):807.Google Scholar
- 57.Filosso PL, Guerrera F, Evangelista A, et al. Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the european association of thoracic surgeons (ESTS) neuroendocrine tumours working group. Eur J Cardiothorac Surg. 2015;48(3):441–7.CrossRefPubMedGoogle Scholar
- 64.Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.CrossRefPubMedGoogle Scholar
- 66.Bongiovanni A, Recine F, Riva N, et al. Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance of 18FDG-PET/CT. Clin Lung Cancer. 2016; https://doi.org/10.1016/j.cllc.2016.11.004.
- 69.Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.CrossRefPubMedGoogle Scholar
- 72.Fazio N, Buzzoni R, Delle Fave G, et al. Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the lung: a subgroup analysis of the phase 3 RADIANT-4 study. Presented at the 2016 North American Neuroendocrine Tumor Society Annual Symposium.Google Scholar
- 73.Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study. Ann Oncol. 2016;27(suppl 6):416O.Google Scholar
- 76.Gagliano T, Gennari G, Tassinari M, et al. The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF. Presented at the 16th European Congress of Endocrinology 2014, Poland, Wroclaw Endocrine Abstracts 2014 35:OC10 2.Google Scholar
- 87.Spada F, Antonuzzo L, Marconcini R, et al. Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an italian multicenter retrospective analysis. J Clin Oncol. 2015;33(15):e15174.Google Scholar
- 88.Papaxoinis G, McCallum L, Nasralla M, Nonaka D. Efficacy of the combination of capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours. Neuroendocrinology. 2016;103:71–71.Google Scholar
- 94.Naraev B, Sharma N, Engelman ES, Bushnell DL, O'Dorisio TM, Halfdanarson TR. The outcome of peptide receptor radionuclide therapy (PRRT) in north american patients with advanced well-differentiated neuroendocrine tumors (WD-NETs). J Clin Oncol. 2012;30(15):e14600.Google Scholar
- 96.US National Institutes of Health. Safety of lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (GI) or lung carcinoids: A pilot, one-arm, open-label, prospective study: The MetNET-2 trial. https://clinicaltrials.gov/ct2/show/NCT02823691. Accessed 12 May 2017.
- 97.US National Institutes of Health. A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or Lung Origin (the DUNE trial). https://clinicaltrials.gov/ct2/show/NCT03095274. Accessed 12 May 2017.
- 98.US National Institutes of Health. DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. https://clinicaltrials.gov/ct2/show/NCT02834013. Accessed 12 May 2017.
- 99.US National Institutes of Health. Phase II study of ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors. https://clinicaltrials.gov/ct2/show/NCT02575300. Accessed 12 May 2017.
- 100.US National Institutes of Health. A phase 3, prospective, randomized, double-blind, multi-center study of the efficacy and safety of lanreotide Autogel/Depot 120 mg plus BSC vs. placebo plus BSC for tumor control in subjects with well differentiated, metastatic and/or unresectable, typical or atypical, lung Neuroendocrine tumors. https://clinicaltrials.gov/ct2/show/NCT02683941. Accessed 12 May 2017.
- 101.US National Institutes of Health. Efficacy and safety of lanreotide ATG 120 mg in combination with temozolomide in subjects with progressive well differentiated thoracic neuroendocrine tumors. A phase II, multicentre, single arm, open-label trial. https://clinicaltrials.gov/ct2/show/NCT02698410. Accessed 12 May 2017.
- 102.US National Institutes of Health. Phase II study of single agent regorafenib in patients with Advanced/Metastatic neuroendocrine tumors. https://clinicaltrials.gov/ct2/show/NCT02259725. Accessed 12 May 2017.
- 103.US National Institutes of Health. An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment EUDRACT. https://clinicaltrials.gov/ct2/show/NCT02259725. Accessed12 May 2017.